, PROGRESS IN BRAIN RESEARCH
VOLUME 172
SEROTONIN–DOPAMINE INTERACTION:
EXPERIMENTAL EVIDENCE AND
THERAPEUTIC RELEVANCE
EDITED BY
GIUSEPPE DI GIOVANNI
Dipartimento di Medicina Sperimentale,
Sezione di Fisiologia Umana ‘‘G. Pagano’’, Università degli Studi di Palermo, Palermo, Italy
VINCENZO DI MATTEO and ENNIO ESPOSITO
Istituto di Ricerche Farmacologiche ‘‘Mario Negri’’,
Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
AMSTERDAM – BOSTON – HEIDELBERG – LONDON – NEW YORK – OXFORD
PARIS – SAN DIEGO – SAN FRANCISCO – SINGAPORE – SYDNEY – TOKYO
,Elsevier
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands
Linacre House, Jordan Hill, Oxford OX2 8DP, UK
First edition 2008
Copyright r 2008 Elsevier B.V. All rights reserved
No part of this publication may be reproduced, stored in a retrieval system
or transmitted in any form or by any means electronic, mechanical, photocopying,
recording or otherwise without the prior written permission of the publisher
Permissions may be sought directly from Elsevier’s Science & Technology Rights
Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333;
email: . Alternatively you can submit your request online by
visiting the Elsevier web site at http://www.elsevier.com/locate/permissions, and selecting
Obtaining permission to use Elsevier material
Notice
No responsibility is assumed by the publisher for any injury and/or damage to persons
or property as a matter of products liability, negligence or otherwise, or from any use
or operation of any methods, products, instructions or ideas contained in the material
herein. Because of rapid advances in the medical sciences, in particular, independent
verification of diagnoses and drug dosages should be made
British Library Cataloguing in Publication Data
A catalogue record for this book is available from the British Library
Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress
ISBN: 978-0-444-53235-0 (this volume)
ISSN: 0079-6123 (Series)
For information on all Elsevier publications
visit our website at books.elsevier.com
Printed and bound in Hungary
08 09 10 11 12 10 9 8 7 6 5 4 3 2 1
, List of contributors
J.M.C. Alfaro, Laboratorio de Neurociencias, División de Estudios de Posgrado, Facultad de Ciencias
Médicas y Biológicas ‘‘Dr. Ignacio Chávez’’, Universidad Michoacana de San Nicolás de Hidalgo,
Morelai, Mich., Mexico
P. Anguiano-Rodrı́guez, Laboratorio de Neurofisiologı́a Experimental, Centro de Investigación Biomédica
de Michoacán, Instituto Mexicano del Seguro Social, Morelai, Mich., Mexico
M.H. Baumann, Clinical Psychopharmacology Section, Intramural Research Program, National Institute
on Drug Abuse, National Institutes of Health, DHHS, Baltimore, MD, USA
A. Benigno, Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana, Universita‘ di Palermo,
Corso Tuköry, Palermo, Italy
K.A. Berg, Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX,
USA
A. Björklund, Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical
Science, Lund University, Lund, Sweden
B.E. Blough, Chemistry and Life Sciences Group, Research Triangle Institute International, Research
Triangle Park, NC, USA
V. Boulougouris, Department of Experimental Psychology and the Behavioural and Clinical Neuroscience
Institute (BCNI), University of Cambridge, Cambridge, UK
J.M. Brotchie, Toronto Western Research Institute, Toronto, Ont., Canada
M.J. Bubar, Center for Addiction Research, Department of Pharmacology and Toxicology, University of
Texas Medical Branch, Galveston, TX, USA
R.J. Carey, Research and Development (151), VA Medical Center and SUNY Upstate Medical University,
Syracuse, NY, USA
T. Carlsson, Neurobiology Unit, Wallenberg Neuroscience Center; Brain Repair and Imaging in Neural
Systems Unit, Section for Neuroscience, Department of Experimental Medical Science, Lund
University, Lund, Sweden
M. Carta, Neurobiology Unit, Wallenberg Neuroscience Center; Brain Repair and Imaging in Neural
Systems Unit, Section for Neuroscience, Department of Experimental Medical Science, Lund
University, Lund, Sweden
R. Chuang, Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ont.,
Canada
W.P. Clarke, Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX,
USA
I.W. Craig, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry,
King’s College London, Denmark Hill, London, UK
G. Crescimanno, Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana, Università di
Palermo, Corso Tuköry, Palermo, Italy
K.A. Cunningham, Center for Addiction Research, Department of Pharmacology and Toxicology,
University of Texas Medical Branch, Galveston, TX, USA
J. de Almeida, Departament de Neuroquimica, Institut d’Investigacions Biomediques de Barcelona,
Consejo Superior de Investigaciones Cientificas (CSIC), IDIBAPS Rossello, Barcelona, Spain
v
VOLUME 172
SEROTONIN–DOPAMINE INTERACTION:
EXPERIMENTAL EVIDENCE AND
THERAPEUTIC RELEVANCE
EDITED BY
GIUSEPPE DI GIOVANNI
Dipartimento di Medicina Sperimentale,
Sezione di Fisiologia Umana ‘‘G. Pagano’’, Università degli Studi di Palermo, Palermo, Italy
VINCENZO DI MATTEO and ENNIO ESPOSITO
Istituto di Ricerche Farmacologiche ‘‘Mario Negri’’,
Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
AMSTERDAM – BOSTON – HEIDELBERG – LONDON – NEW YORK – OXFORD
PARIS – SAN DIEGO – SAN FRANCISCO – SINGAPORE – SYDNEY – TOKYO
,Elsevier
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands
Linacre House, Jordan Hill, Oxford OX2 8DP, UK
First edition 2008
Copyright r 2008 Elsevier B.V. All rights reserved
No part of this publication may be reproduced, stored in a retrieval system
or transmitted in any form or by any means electronic, mechanical, photocopying,
recording or otherwise without the prior written permission of the publisher
Permissions may be sought directly from Elsevier’s Science & Technology Rights
Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333;
email: . Alternatively you can submit your request online by
visiting the Elsevier web site at http://www.elsevier.com/locate/permissions, and selecting
Obtaining permission to use Elsevier material
Notice
No responsibility is assumed by the publisher for any injury and/or damage to persons
or property as a matter of products liability, negligence or otherwise, or from any use
or operation of any methods, products, instructions or ideas contained in the material
herein. Because of rapid advances in the medical sciences, in particular, independent
verification of diagnoses and drug dosages should be made
British Library Cataloguing in Publication Data
A catalogue record for this book is available from the British Library
Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress
ISBN: 978-0-444-53235-0 (this volume)
ISSN: 0079-6123 (Series)
For information on all Elsevier publications
visit our website at books.elsevier.com
Printed and bound in Hungary
08 09 10 11 12 10 9 8 7 6 5 4 3 2 1
, List of contributors
J.M.C. Alfaro, Laboratorio de Neurociencias, División de Estudios de Posgrado, Facultad de Ciencias
Médicas y Biológicas ‘‘Dr. Ignacio Chávez’’, Universidad Michoacana de San Nicolás de Hidalgo,
Morelai, Mich., Mexico
P. Anguiano-Rodrı́guez, Laboratorio de Neurofisiologı́a Experimental, Centro de Investigación Biomédica
de Michoacán, Instituto Mexicano del Seguro Social, Morelai, Mich., Mexico
M.H. Baumann, Clinical Psychopharmacology Section, Intramural Research Program, National Institute
on Drug Abuse, National Institutes of Health, DHHS, Baltimore, MD, USA
A. Benigno, Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana, Universita‘ di Palermo,
Corso Tuköry, Palermo, Italy
K.A. Berg, Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX,
USA
A. Björklund, Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical
Science, Lund University, Lund, Sweden
B.E. Blough, Chemistry and Life Sciences Group, Research Triangle Institute International, Research
Triangle Park, NC, USA
V. Boulougouris, Department of Experimental Psychology and the Behavioural and Clinical Neuroscience
Institute (BCNI), University of Cambridge, Cambridge, UK
J.M. Brotchie, Toronto Western Research Institute, Toronto, Ont., Canada
M.J. Bubar, Center for Addiction Research, Department of Pharmacology and Toxicology, University of
Texas Medical Branch, Galveston, TX, USA
R.J. Carey, Research and Development (151), VA Medical Center and SUNY Upstate Medical University,
Syracuse, NY, USA
T. Carlsson, Neurobiology Unit, Wallenberg Neuroscience Center; Brain Repair and Imaging in Neural
Systems Unit, Section for Neuroscience, Department of Experimental Medical Science, Lund
University, Lund, Sweden
M. Carta, Neurobiology Unit, Wallenberg Neuroscience Center; Brain Repair and Imaging in Neural
Systems Unit, Section for Neuroscience, Department of Experimental Medical Science, Lund
University, Lund, Sweden
R. Chuang, Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ont.,
Canada
W.P. Clarke, Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX,
USA
I.W. Craig, MRC Social, Genetic and Developmental Psychiatry (SGDP) Centre, Institute of Psychiatry,
King’s College London, Denmark Hill, London, UK
G. Crescimanno, Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana, Università di
Palermo, Corso Tuköry, Palermo, Italy
K.A. Cunningham, Center for Addiction Research, Department of Pharmacology and Toxicology,
University of Texas Medical Branch, Galveston, TX, USA
J. de Almeida, Departament de Neuroquimica, Institut d’Investigacions Biomediques de Barcelona,
Consejo Superior de Investigaciones Cientificas (CSIC), IDIBAPS Rossello, Barcelona, Spain
v
